Defibrillation thresholds in hypertrophic cardiomyopathy

Journal of Cardiovascular Electrophysiology

Volumn 22, Issue 5, 2011, Pages 569-572

  Quin, Ernest M ^a,c   Cuoco, Frank A ^a   Forcina, Matthew S ^b   Coker, Jason B ^a   Yoe, Robert H ^a   Spencer III, William H ^a   Fernandes, Valerian L ^a   Nielsen, Christopher D ^a   Sturdivant, J Lacy ^a   Leman, Robert B ^a   Wharton, J Marcus ^a   Gold, Michael R ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b Wake Heart and Vascular Associates ^*  (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

defibrillation threshold; hypertrophic cardiomyopathy; implantable cardioverter defibrillator

Indexed keywords

ADULT; ARTICLE; CONTROLLED STUDY; DEFIBRILLATION; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE MASS; HEART VENTRICLE SEPTUM; HIGH RISK POPULATION; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QRS COMPLEX;

CARDIOMYOPATHY, HYPERTROPHIC; DEFIBRILLATORS, IMPLANTABLE; DIFFERENTIAL THRESHOLD; ELECTRIC COUNTERSHOCK; FEMALE; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 79955883872     PISSN: 10453873     EISSN: 15408167     Source Type: Journal    
DOI: 10.1111/j.1540-8167.2010.01943.x     Document Type: Article

References (21)

1. Calvi V, Dugo D, Capodanno D, Rancio R, Di Grazia A, Liotta C, Puzzangara E, Ragusa A, Arestia A, Tamburino C,: Intraoperative defibrillation threshold testing during implantable cardioverter-defibrillator insertion: Do we really need it? Am Heart J 2010; 159: 98-102.
2. Healey JS, Dorian P, Mitchell LB, Talajic M, Phillipon F, Simpson C, Yee R, Morillo CA, Lamy A, Basta M, Birnie DH, Wang X, Nair GM, Crystal E, Kerr CR, Connolly SJ,; CREDIT Investigators: Canadian registry of ICD implant testing procedures (CREDIT): Current practice, risks, and costs of intraoperative defibrillation testing. J Cardiovasc Electrophysiol 2010; 21: 177-182.
3. Blatt JA, Poole JE, Johnson GW, Callans DJ, Raitt MH, Reddy RK, Marchlinski FE, Yee R, Guarnieri T, Talajic M, Wilber DJ, Anderson J, Chung K, Wong WS, Mark DB, Lee KL, Bardy GH,; SCD-HeFT Investigators: No benefit from defibrillation threshold testing in the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial). J Am Coll Cardiol 2008; 12: 551-556.
4. Epstein AE, Ellenbogen KA, Kirk KA, Kay GN, Dailey SM, Plumb VJ,: Clinical characteristics and outcome of patients with high defibrillation thresholds: A multicenter study. Circulation 1992; 86: 1206-1216.
5. Gold MR, Khalighi K, Kavesh NG, Daly B, Peters RW, Shorofsky SR,: Clinical predictors of transvenous biphasic defibrillation thresholds. Am J Cardiol 1997; 79: 1623-1627. (Pubitemid 27339471)
6. Khaligi K, Daly B, Leino EV, Shorofsky SR, Kavesh NG, Peters RW, Gold MR,: Clinical predictors of transvenous defibrillation energy requirements. Am J Cardiol 1997; 79: 150-153. (Pubitemid 127673701)
7. Raitt MH, Johnson G, Dolack GL, Poole JE, Kudenchuk PJ, Bardy GH,: Clinical predictors of the defibrillaton threshold with the unipolar implantable defibrillation system. J Am Coll Cardiol 1995; 25: 1576-1583.
8. Nagai T, Kurita T, Satomi K, Noda T, Okamura H, Shimizu W, Suyama K, Aihara N, Kobayashi J, Kamakura S,: QRS prolongation is associated with high defibrillation thresholds during cardioverter-defibrillator implantations in patients with hypertrophic cardiomyopathy. Circulation Journal 2009; 73: 1028-1032.
9. Almquist AK, Montgomery JV, Haas TS, Maron BJ,: Cardioverter- defibrillator implantation in high-risk patients with hypertrophic cardiomyopathy. Heart Rhythm 2005; 2: 814-819. (Pubitemid 41038399)
10. Boriani G, Rapezzi C, Biffi M, Branzi A,: Hypertrophic cardiomyopathy with massive hypertrophy, amiodarone treatment and high defibrillation threshold at cardioverter-defibrillator implant. Int J Cardiol 2002; 83: 171-173. (Pubitemid 34451084)
11. Epstein AE, DiMarco JP, Ellenbogen KA, Estes NAM 3rd, Freedman RA, Gettes LS, Gillinov AM, Gregoratos G, Hammill SC, Hayes DL, Hlatky MA, Newby LK, Page RL, Schoenfeld MH, Silka MJ, Stevenson LW, Sweeney MO,: ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities. J Am Coll Cardiol 2008; 51: e1-e62.
12. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise J, Solomon S, Spencer KT, St John Sutton F, Stewart W,; American Society of Echocardiography's Nomenclature and Standards Committee; Task Force on Chamber Quantification; American College of Cardiology Echocardiography Committee; American Heart Association; European Association of Echocardiography, European Society of Cardiology: Recommendations for chamber quantification: A report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group. J Am Soc Echocardiogr 2005; 18: 1440-1463.
13. Gold MR, Olsovsky MR, Pelini MA, Peters RW, Shorofsky SR,: Comparison of single- and dual-coil active pectoral defibrillation lead systems. J Am Coll Cardiol 1998; 31: 1391-1394. (Pubitemid 28219134)
14. Shorofsky SR, Gold MR,: Effects of waveform and polarity on defibrillation thresholds in humans using a transvenous lead system. Am J Cardiol 1996; 78: 313-316. (Pubitemid 26265274)
15. Olsovsky MR, Hodgson DM, Shorofsky SR, Kavesh NG, Gold MR,: Effect of biphasic waveforms on transvenous defibrillation thresholds in patients with coronary artery disease. Am J Cardiol 1997; 80: 1098-1100. (Pubitemid 27459220)
16. Gold MR, Foster AH, Shorofsky SR,: Lead system optimization for transvenous defibrillation. Am J Cardiol 1997; 80: 1163-1167. (Pubitemid 27467404)
17. Kroll MW, Efimov IR, Tchou PJ,: Present understanding of shock polarity for internal defibrillation: The obvious and non-obvious clinical implications. Pacing Clin Electrophysiol 2006; 29: 885-891. (Pubitemid 44222143)
18. Maron MS, Olivotto I, Betocchi S, Casey SA, Lesser JR, Losi MA, Cecchi F, Maron BJ,: Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 2003; 348: 295-303. (Pubitemid 36119984)
19. Cuoco FA, Spencer WH 3rd, Fernandes VL, Nielsen CD, Nagueh S, Sturdivant JL, Leman RB, Wharton JM, Gold MR,: Implantable cardioverter-defibrillator therapy for primary prevention of sudden death after alcohol septal ablation of hypertrophic cardiomyopathy. J Am Coll Cardiol 2008; 52: 1718-1723.
20. Runquist LH, Nielsen CD, Killip D, Gazes P, Spencer WH 3rd,: Electrocardiographic findings after alcohol septal ablation therapy for obstructive hypertrophic cardiomyopathy. Am J Cardiol 2002; 90: 1020-1022. (Pubitemid 35232634)
21. Fernandes VL, Neilsen C, Nagueh SF, Herin AE, Slifka C, Franklin J, Spencer WH 3rd,: Follow-up of alcohol septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: The Baylor and Medical University of South Carolina experience 1996 to 2007. J Am Coll Cardiol 2008; 1: 561-570.